Zydus Lifesciences wins USFDA nod for Chlorpromazine Hydrochloride Injection for certain mental disorders

Zydus Lifesciences has received approval from the USFDA for their Chlorpromazine Hydrochloride Injection, which is used to treat certain mental disorders. The medication has been found effective in managing conditions such as schizophrenia and bipolar disorder. By obtaining this approval, Zydus Lifesciences has expanded their portfolio of mental health medications available in the United States. Additionally, the company continues to focus on research and development to bring innovative treatment options to patients. Cookies are used on the website for analytics, advertising, and site improvement purposes, with continued use indicating consent to their use.

Source link

error: Content is protected !!